FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer By Ogkologos - July 11, 2025 630 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Are New Immune-Based Treatments for Kidney and Pancreatic Cancer on the... April 23, 2025 Studies Provide First Evidence That Breastfeeding after Breast Cancer Is Safe September 8, 2024 Pazopanib Shows Promise for Children, Adults with Soft Tissue Sarcomas September 9, 2020 Genetic discovery could guide treatment for aggressive childhood cancer June 28, 2021 Load more HOT NEWS Research with integrity – why building networks is vital for integrity Adding 24 Months of ADT Improves Metastasis-Free Survival in Patients with... Prize winning early detection research Substantial Clinical Activity of Teclistamab in Patients with Heavily Pretreated Relapsed...
